株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ドラベ症候群(DS):市場洞察、疫学、および2028年までの市場予測 

Dravet Syndrome (DS) - Market Insights, Epidemiology and Market Forecast-2028

発行 DelveInsight Business Research LLP 商品コード 905933
出版日 ページ情報 英文 120 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
ドラベ症候群(DS):市場洞察、疫学、および2028年までの市場予測  Dravet Syndrome (DS) - Market Insights, Epidemiology and Market Forecast-2028
出版日: 2019年08月01日 ページ情報: 英文 120 Pages
概要

当レポートは世界のドラベ症候群(DS)について調査しており、疾患の概要や疫学、患者人口、主要9か国(米国・ドイツ・フランス・イタリア・スペイン・英国・オーストリア・日本・オーストラリア)の市場分析、主要企業の製品などの情報について報告しています。

目次

第1章 重要な洞察

第2章 ドラベ症候群市場の概要

  • 2017年:市場シェア(%)分布
  • 2028年:市場シェア(%)分布

第3章 ドラベ症候群:疾患の背景および概要

  • イントロダクション
  • 臨床的特徴
    • てんかん
    • 認知
    • 運動障害
    • 突然死
  • ドラベ症候群の遺伝学
    • ナトリウムチャネルa1サブユニット遺伝子(SCN1A)およびドラベット症候群およびの関連
    • 電圧ゲートナトリウムチャネル変異の機能的側面
    • SCN1A変異の検出
    • 継承モードおよびパターン
    • SCN1Aの変化を伴わないドラベ症候群
  • 徴候および症状
  • 病態生理
  • 診断
    • 鑑別診断

第4章 疫学および患者人口

  • 主な調査結果
  • 主要9か国におけるドラベ症候群の総発生率

第5章 ドラベ症候群の国別疫学

第6章 米国

  • 仮定および根拠
  • ドラベ症候群の事件人口
  • ドラベ症候群に関連する突然変異
    • クラス別:突然変異の発生率
    • 型別:突然変異の発生率
  • 発作関連症例
  • 性別発生率
  • 年齢別発生率
  • 死亡率

第7章 欧州5ヶ国

  • 仮定および根拠

第8章 ドイツ

第9章 フランス

第10章 イタリア

第11章 スペイン

第12章 英国

第13章 オーストリア

第14章 日本

第15章 オーストラリア

第16章 ドラベ症候群の治療

  • 現在の治療法
    • 第1選択療法:バルプロ酸およびクロバザム
    • 第2選択療法
    • 第3選択療法
  • 治療アルゴリズム

第17章 潜在的な需要

第18章 市販薬

  • Diacomit:Biocodex
    • 薬の説明
    • 作用機序
    • 規制のマイルストーン
    • 長所および短所
    • 安全性および有効性
    • 製品プロファイル
  • Epidiolex:GW Pharmaceuticals

第19章 新しい治療法

  • FINTEPLA:Zogenix
    • 製品説明
    • その他の発達活動
    • 規制のマイルストーン
    • 臨床開発
    • 安全性および有効性
    • 製品プロファイル

第20章 ドラベ症候群:9つの主要市場分析

  • 主な調査結果
  • 主要9か国の総市場規模
  • 治療ライン別:主要9か国の規模

第21章 国別の市場見通し

  • 米国:市場の見通し
  • 米国:市場規模
    • ドラベ症候群の総市場規模
    • 治療ライン(LoT)別:市場規模
  • EU-6諸国:市場の見通し
  • ドイツ:市場規模
  • フランス:市場規模
  • イタリア:市場規模
  • スペイン:市場規模
  • 英国:市場規模
  • オーストリアの市場規模
  • 日本:市場の見通し
  • 日本:市場規模

第22章 市場成長要因

第23章 市場の障壁

第24章 付録

第25章 調査方法

  • 使用されるソース

第26章 DelveInsightのサービス内容

第27章 免責事項

第28章 DelveInsightについて

図表

List of Tables

  • Table 1: Stages of Dravet Syndrome
  • Table 2: Genetic background of Dravet syndrome
  • Table 3: Total Incident Population of Dravet Syndrome in 9MM (2017-2028)
  • Table 4: Incident Population of Dravet Syndrome in the United States (2017-2028)
  • Table 5: Mutation positive cases of Dravet Syndrome in the United States (2017-2028)
  • Table 6: Incidence of Dravet Syndrome by Mutation Class in the United States (2017-2028)
  • Table 7: Incidence of Dravet Syndrome by Mutation Type in the United States (2017-2028)
  • Table 8: Seizure associated cases of Dravet Syndrome in the United States (2017-2028)
  • Table 9: Gender specific Incidence of Dravet Syndrome in the United States (2017-2028)
  • Table 10: Age specific Incidence of Dravet Syndrome in the United States (2017-2028)
  • Table 11: Number of Deaths Associated with Dravet Syndrome in the United States (2017-2028)
  • Table 12: Incident Population of Dravet Syndrome in Germany (2017-2028)
  • Table 13: Mutation positive cases of Dravet Syndrome in Germany (2017-2028)
  • Table 14: Incidence of Dravet Syndrome by Mutation Class in Germany (2017-2028)
  • Table 15: Incidence of Dravet Syndrome by Mutation Type in Germany (2017-2028)
  • Table 16: Seizure associated cases of Dravet Syndrome in Germany (2017-2028)
  • Table 17: Gender specific Incidence of Dravet Syndrome in Germany (2017-2028)
  • Table 18: Age specific Incidence of Dravet Syndrome in Germany (2017-2028)
  • Table 19: Number of Deaths Associated with Dravet Syndrome in Germany (2017-2028)
  • Table 20: Incident Population of Dravet Syndrome in France (2017-2028)
  • Table 21: Mutation positive cases of Dravet Syndrome in France (2017-2028)
  • Table 22: Incidence of Dravet Syndrome by Mutation Class in France (2017-2028)
  • Table 23: Incidence of Dravet Syndrome by Mutation Type in France (2017-2028)
  • Table 24: Seizure associated cases of Dravet Syndrome in France (2017-2028)
  • Table 25: Gender specific Incidence of Dravet Syndrome in France (2017-2028)
  • Table 26: Age specific Incidence of Dravet Syndrome in France (2017-2028)
  • Table 27: Number of Deaths Associated with Dravet Syndrome in France (2017-2028)
  • Table 28: Incident Population of Dravet Syndrome in Italy (2017-2028)
  • Table 29: Mutation positive cases of Dravet Syndrome in Italy (2017-2028)
  • Table 30: Incidence of Dravet Syndrome by Mutation Class in Italy (2017-2028)
  • Table 31: Incidence of Dravet Syndrome by Mutation Type in Italy (2017-2028)
  • Table 32: Seizure associated cases of Dravet Syndrome in Italy (2017-2028)
  • Table 33: Gender specific Incidence of Dravet Syndrome in Italy (2017-2028)
  • Table 34: Age specific Incidence of Dravet Syndrome in Italy (2017-2028)
  • Table 35: Number of Deaths Associated with Dravet Syndrome in Italy (2017-2028)
  • Table 36: Incident Population of Dravet Syndrome in Spain (2017-2028)
  • Table 37: Mutation positive cases of Dravet Syndrome in Spain (2017-2028)
  • Table 38: Incidence of Dravet Syndrome by Mutation Class in Spain (2017-2028)
  • Table 39: Incidence of Dravet Syndrome by Mutation Type in Spain (2017-2028)
  • Table 40: Seizure associated cases of Dravet Syndrome in Spain (2017-2028)
  • Table 41: Gender specific Incidence of Dravet Syndrome in Spain (2017-2028)
  • Table 42: Age specific Incidence of Dravet Syndrome in Spain (2017-2028)
  • Table 43: Number of Deaths Associated with Dravet Syndrome in Spain (2017-2028)
  • Table 44: Incident Population of Dravet Syndrome in the United Kingdom (2017-2028)
  • Table 45: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017-2028)
  • Table 46: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017-2028)
  • Table 47: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017-2028)
  • Table 48: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017-2028)
  • Table 49: Gender specific Incidence of Dravet Syndrome in the United Kingdom (2017-2028)
  • Table 50: Age specific Incidence of Dravet Syndrome in the United Kingdom (2017-2028)
  • Table 51: Number of Deaths Associated with Dravet Syndrome in the United Kingdom (2017-2028)
  • Table 52: Incident Population of Dravet Syndrome in Austria (2017-2028)
  • Table 53: Mutation positive cases of Dravet Syndrome in Austria (2017-2028)
  • Table 54: Incidence of Dravet Syndrome by Mutation Class in Austria (2017-2028)
  • Table 55: Incidence of Dravet Syndrome by Mutation Type in Austria (2017-2028)
  • Table 56: Seizure associated cases of Dravet Syndrome in Austria (2017-2028)
  • Table 57: Gender specific Incidence of Dravet Syndrome in Austria (2017-2028)
  • Table 58: Age specific Incidence of Dravet Syndrome in Austria (2017-2028)
  • Table 59: Number of Deaths Associated with Dravet Syndrome in Austria (2017-2028)
  • Table 60: Incident Population of Dravet Syndrome in Japan (2017-2028)
  • Table 61: Mutation positive cases of Dravet Syndrome in Japan (2017-2028)
  • Table 62: Incidence of Dravet Syndrome by Mutation Class in Japan (2017-2028)
  • Table 63: Incidence of Dravet Syndrome by Mutation Type in Japan (2017-2028)
  • Table 64: Seizure associated cases of Dravet Syndrome in Japan (2017-2028)
  • Table 65: Gender specific Incidence of Dravet Syndrome in Japan (2017-2028)
  • Table 66: Age specific Incidence of Dravet Syndrome in Japan (2017-2028)
  • Table 67: Number of Deaths Associated with Dravet Syndrome in Japan (2017-2028)
  • Table 68: Incident Population of Dravet Syndrome in Australia (2017-2028)
  • Table 69: Mutation positive cases of Dravet Syndrome in Australia (2017-2028)
  • Table 70: Incidence of Dravet Syndrome by Mutation Class in Australia (2017-2028)
  • Table 71: Incidence of Dravet Syndrome by Mutation Type in Australia (2017-2028)
  • Table 72: Seizure associated cases of Dravet Syndrome in Australia (2017-2028)
  • Table 73: Gender specific Incidence of Dravet Syndrome in Australia (2017-2028)
  • Table 74: Age specific Incidence of Dravet Syndrome in Australia (2017-2028)
  • Table 75: Number of Deaths Associated with Dravet Syndrome in Australia (2017-2028)
  • Table 76: ZX008 Clinical Trial Description, 2019
  • Table 77: TAK-935, Clinical Trial Description, 2019
  • Table 78: 9 Major Market Size of Dravet Syndrome in USD Million (2017-2028)
  • Table 79: 9MM Size of Dravet Syndrome by LoT in USD Million (2017-2028)
  • Table 80: The US Market Dravet Syndrome in USD Million (2017-2028)
  • Table 81: The US Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Table 82: Germany Market of Dravet Syndrome in USD Million (2017-2028)
  • Table 83: Germany Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Table 84: France Market of Dravet Syndrome in USD Million (2017-2028)
  • Table 85 France Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Table 86: Italy Market of Dravet Syndrome in USD Million (2017-2028)
  • Table 87: Italy Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Table 88: Spain Market of Dravet Syndrome in USD Million (2017-2028)
  • Table 89: Spain Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Table 90: UK Market of Dravet Syndrome in USD Million (2017-2028)
  • Table 91: UK Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Table 92: Austria Market of Dravet Syndrome in USD Million (2017-2028)
  • Table 93: Austria Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Table 94: Japan Market of Dravet Syndrome in USD Million (2017-2028)
  • Table 95: Japan Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Table 96: Australia Market of Dravet Syndrome in USD Million (2017-2028)
  • Table 97:Australia Dravet Syndrome Market Size by LoT in USD Million (2017-2028)

List of Figures

  • Figure 1: Schematic representation of clinical manifestations of Dravet syndrome
  • Figure 2: Differential diagnosis of Dravet syndrome in the course of the disease
  • Figure 3: Total Incident Population of Dravet Syndrome in 9 MM (2017-2028)
  • Figure 4: Incident Population of Dravet Syndrome in the United States (2017-2028)
  • Figure 5: Mutation positive cases of Dravet Syndrome in the United States (2017-2028)
  • Figure 6: Incidence of Dravet Syndrome by Mutation Class in the United States (2017-2028)
  • Figure 7: Incidence of Dravet Syndrome by Mutation Type in the United States (2017-2028)
  • Figure 8: Seizure associated cases of Dravet Syndrome in the United States (2017-2028)
  • Figure 9: Gender specific Incidence of Dravet Syndrome in the United States (2017-2028)
  • Figure 10: Age specific Incidence of Dravet Syndrome in the United States (2017-2028)
  • Figure 11: Number of Deaths Associated with Dravet Syndrome in the United States (2017-2028)
  • Figure 12: Incident Population of Dravet Syndrome in Germany (2017-2028)
  • Figure 13: Mutation positive cases of Dravet Syndrome in Germany (2017-2028)
  • Figure 14: Incidence of Dravet Syndrome by Mutation Class in Germany (2017-2028)
  • Figure 15: Incidence of Dravet Syndrome by Mutation Type in Germany (2017-2028)
  • Figure 16: Seizure associated cases of Dravet Syndrome in Germany (2017-2028)
  • Figure 17: Gender specific Incidence of Dravet Syndrome in Germany (2017-2028)
  • Figure 18: Age specific Incidence of Dravet Syndrome in Germany 2017-2028)
  • Figure 19: Number of Deaths Associated with Dravet Syndrome in Germany (2017-2028)
  • Figure 20: Incident Population of Dravet Syndrome in France (2017-2028)
  • Figure 21: Mutation positive cases of Dravet Syndrome in France (2017-2028)
  • Figure 22: Incidence of Dravet Syndrome by Mutation Class in France (2017-2028)
  • Figure 23: Incidence of Dravet Syndrome by Mutation Type in France (2017-2028)
  • Figure 24: Seizure associated cases of Dravet Syndrome in France (2017-2028)
  • Figure 25: Gender specific Incidence of Dravet Syndrome in France (2017-2028)
  • Figure 26: Age specific Incidence of Dravet Syndrome in France (2017-2028)
  • Figure 27: Number of Deaths Associated with Dravet Syndrome in France (2017-2028)
  • Figure 28: Incident Population of Dravet Syndrome in Italy (2017-2028)
  • Figure 29: Mutation positive cases of Dravet Syndrome in Italy (2017-2028)
  • Figure 30: Incidence of Dravet Syndrome by Mutation Class in Italy (2017-2028)
  • Figure 31: Incidence of Dravet Syndrome by Mutation Type in Italy (2017-2028)
  • Figure 32: Seizure associated cases of Dravet Syndrome in Italy (2017-2028)
  • Figure 33: Gender specific Incidence of Dravet Syndrome in Italy (2017-2028)
  • Figure 34: Age specific Incidence of Dravet Syndrome in Italy (2017-2028)
  • Figure 35: Number of Deaths Associated with Dravet Syndrome in Italy (2017-2028)
  • Figure 36: Incident Population of Dravet Syndrome in Spain (2017-2028)
  • Figure 37: Mutation positive cases of Dravet Syndrome in Spain (2017-2028)
  • Figure 38: Incidence of Dravet Syndrome by Mutation Class in Spain (2017-2028)
  • Figure 39: Incidence of Dravet Syndrome by Mutation Type in Spain (2017-2028)
  • Figure 40: Seizure associated cases of Dravet Syndrome in Spain (2017-2028)
  • Figure 41: Gender specific Incidence of Dravet Syndrome in Spain (2017-2028)
  • Figure 42: Age specific Incidence of Dravet Syndrome in Spain (2017-2028)
  • Figure 43: Number of Deaths Associated with Dravet Syndrome in Spain (2017-2028)
  • Figure 44: Incident Population of Dravet Syndrome in the United Kingdom (2017-2028)
  • Figure 45: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017-2028)
  • Figure 46: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017-2028)
  • Figure 47: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017-2028)
  • Figure 48: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017-2028)
  • Figure 49: Gender specific Incidence of Dravet Syndrome in the United Kingdom (2017-2028)
  • Figure 50: Age specific Incidence of Dravet Syndrome in the United Kingdom (2017-2028)
  • Figure 51: Number of Deaths Associated with Dravet Syndrome in the United Kingdom (2017-2028)
  • Figure 52: Incident Population of Dravet Syndrome in Austria (2017-2028)
  • Figure 53: Mutation positive cases of Dravet Syndrome in Austria (2017-2028)
  • Figure 54: Incidence of Dravet Syndrome by Mutation Class in Austria (2017-2028)
  • Figure 55: Incidence of Dravet Syndrome by Mutation Type in Austria (2017-2028)
  • Figure 56: Seizure associated cases of Dravet Syndrome in Austria (2017-2028)
  • Figure 57: Gender specific Incidence of Dravet Syndrome in Austria (2017-2028)
  • Figure 58: Age specific Incidence of Dravet Syndrome in Austria (2017-2028)
  • Figure 59: Number of Deaths Associated with Dravet Syndrome in Austria (2017-2028)
  • Figure 60: Incident Population of Dravet Syndrome in Japan (2017-2028)
  • Figure 61: Mutation positive cases of Dravet Syndrome in Japan (2017-2028)
  • Figure 62: Incidence of Dravet Syndrome by Mutation Class in Japan (2017-2028)
  • Figure 63: Incidence of Dravet Syndrome by Mutation Type in Japan (2017-2028)
  • Figure 64: Seizure associated cases of Dravet Syndrome in Japan (2017-2028)
  • Figure 65: Gender specific Incidence of Dravet Syndrome in Japan (2017-2028)
  • Figure 66: Age specific Incidence of Dravet Syndrome in Japan (2017-2028)
  • Figure 67: Number of Deaths Associated with Dravet Syndrome in Japan (2017-2028)
  • Figure 68: Incident Population of Dravet Syndrome in Australia (2017-2028)
  • Figure 69: Mutation positive cases of Dravet Syndrome in Australia (2017-2028)
  • Figure 70: Incidence of Dravet Syndrome by Mutation Class in Australia (2017-2028)
  • Figure 71: Incidence of Dravet Syndrome by Mutation Type in Australia (2017-2028)
  • Figure 72: Seizure associated cases of Dravet Syndrome in Australia (2017-2028)
  • Figure 73: Gender specific Incidence of Dravet Syndrome in Australia (2017-2028)
  • Figure 74: Age specific Incidence of Dravet Syndrome in Australia (2017-2028)
  • Figure 75: Number of Deaths Associated with Dravet Syndrome in Australia (2017-2028)
  • Figure 76: Treatment algorithm of epilepsy in Dravet syndrome.
  • Figure 77: Unmet Needs for Dravet Syndrome
  • Figure 78: 9 Major Market Size of Dravet Syndrome in USD Million (2017-2028)
  • Figure 79: 9 Major Market Size of Dravet Syndrome by Line of Treatment in USD Million (2017-2028)
  • Figure 80: Market Size of Dravet Syndrome in the United States, USD Millions (2017-2028)
  • Figure 81: The U.S. Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Figure 82: Market Size of Dravet Syndrome in the Germany, USD Millions (2017-2028)
  • Figure 83: Germany Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Figure 84: Market Size of Dravet Syndrome in France, USD Millions (2017-2028)
  • Figure 85: France Dravet Syndrome Market Size by Therapies in USD Million (2017-2028)
  • Figure 86: Market Size of Dravet Syndrome in Italy, USD Millions (2017-2028)
  • Figure 87: Italy Dravet Syndrome Market Size by Therapies in USD Million (2017-2028)
  • Figure 88: Market Size of Dravet Syndrome in Spain, USD Millions (2017-2028)
  • Figure 89: Spain Dravet Syndrome Market Size by Therapies in USD Million (2017-2028)
  • Figure 90: Market Size of Dravet Syndrome in UK, USD Millions (2017-2028)
  • Figure 91: The UK Dravet Syndrome Market Size by Therapies in USD Million (2017-2028)
  • Figure 92: Market Size of Dravet Syndrome in Austria, USD Millions (2017-2028)
  • Figure 93: Austria Dravet Syndrome Market Size by Therapies in USD Million (2017-2028)
  • Figure 94: Market Size of Dravet Syndrome in Japan, USD Millions (2017-2028)
  • Figure 95: Japan Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Figure 96: Market Size of Dravet Syndrome in Australia, USD Millions (2017-2028)
  • Figure 97: Australia Dravet Syndrome Market Size by LoT in USD Million (2017-2028)
  • Figure 98: Market Drivers of Dravet Syndrome
  • Figure 99:Market Barriers of Dravet Syndrome
目次
Product Code: DIMI0506

DelveInsight's 'Dravet Syndrome (DS) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of DS in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom),Japan, Australia and Austria.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Dravet Syndrome (DS) from 2017 to 2028 segmented by nine major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
  • Australia
  • Austria

Study Period: 2017-2028

Dravet Syndrome (DS) - Disease Understanding and Treatment Algorithm

The DelveInsight Dravet Syndrome (DS) market report gives the thorough understanding of the Dravet Syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Dravet Syndrome in the US, Europe, Japan, Australia and Austria.

Dravet Syndrome Epidemiology

The Dravet Syndrome (DS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 9 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident population, incidence of Dravet Syndrome by Mutation Class, incidence of Dravet Syndrome by Mutation Type, seizure associated cases, gender-specific incident cases and age-specific incident cases) scenario of Dravet Syndrome (DS) in the 9MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan, Australia and Austria from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Dravet Syndrome (DS) in 7 MM was found to be 36,301, in the year 2017.

Dravet Syndrome Drug Chapters

This segment of the Dravet Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast solely focuses on the market revenue generated by the pharmacological treatment. Pharmacological management of Dravet syndrome focuses largely on the use antiepileptic drugs such as Valproic Acid, Clobazam, Topiramate, Levetiracetam, Zonisamide and Stiripentol. Detailed chapter for upcoming therapies like ZX008 (Zogenix) have been covered in the report.

Dravet Syndrome Market Outlook

The Dravet Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Dravet Syndrome in 9MM was found to be USD 112.88 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.

Dravet Syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Dravet Syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Dravet Syndrome Report Key Strengths

  • 10 Year Forecast
  • 9MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Dravet Syndrome Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Dravet Syndrome market
  • Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome market
  • To understand the future market competition in the Dravet Syndrome market.

Table of Contents

1. Key Insights

2. Dravet Syndrome Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Dravet Syndrome in 2017
  • 2.2. Market Share (%) Distribution of Dravet Syndrome in 2028

3. Dravet Syndrome: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Clinical Features of Dravet Syndrome
    • 3.2.1. Epilepsy
    • 3.2.2. Cognition
    • 3.2.3. Movement disorders
    • 3.2.4. Sudden Death
  • 3.3. Genetics of Dravet Syndrome
    • 3.3.1. Sodium Channel a1 Subunit Gene (SCN1A) and its association with Dravet Syndrome
    • 3.3.2. Functional aspects of voltage gate sodium channel mutations
    • 3.3.3. Detection of SCN1A mutations
    • 3.3.4. Inheritance mode and pattern
    • 3.3.5. Dravet Syndrome without SCN1A Alterations
  • 3.4. Signs and Symptoms of Dravet Syndrome
  • 3.5. Pathophysiology
  • 3.6. Diagnosis of Dravet Syndrome
    • 3.6.1. Differential diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Incidence of Dravet Syndrome in 9MM

5. Country Wise-Epidemiology of Dravet Syndrome

6. United States

  • 6.1. Assumptions and Rationale
  • 6.2. Incident Population of Dravet Syndrome
  • 6.3. Mutations associated with Dravet Syndrome
    • 6.3.1. Incidence of Dravet Syndrome by Mutation Class
    • 6.3.2. Incidence of Dravet Syndrome by Mutation Type
  • 6.4. Seizure associated cases of Dravet Syndrome
  • 6.5. Gender specific Incidence of Dravet Syndrome
  • 6.6. Age specific Incidence of Dravet Syndrome
  • 6.7. Mortality associated with Dravet Syndrome

7. EU-5

  • 7.1. Assumptions and Rationale

8. Germany

  • 8.1. Incident Population of Dravet Syndrome
  • 8.2. Mutations associated with Dravet Syndrome
    • 8.2.1. Incidence of Dravet Syndrome by Mutation Class
    • 8.2.2. Incidence of Dravet Syndrome by Mutation Type
  • 8.3. Seizure associated cases of Dravet Syndrome
  • 8.4. Gender specific Incidence of Dravet Syndrome
  • 8.5. Age specific Incidence of Dravet Syndrome
  • 8.6. Mortality associated with Dravet Syndrome

9. France

  • 9.1. Incident Population of Dravet Syndrome
  • 9.2. Mutations associated with Dravet Syndrome
    • 9.2.1. Incidence of Dravet Syndrome by Mutation Class
    • 9.2.2. Incidence of Dravet Syndrome by Mutation Type
  • 9.3. Seizure associated cases of Dravet Syndrome
  • 9.4. Gender specific Incidence of Dravet Syndrome
  • 9.5. Age specific Incidence of Dravet Syndrome
  • 9.6. Mortality associated with Dravet Syndrome

10. Italy

  • 10.1. Incident Population of Dravet Syndrome
  • 10.2. Mutations associated with Dravet Syndrome
    • 10.2.1. Incidence of Dravet Syndrome by Mutation Class
    • 10.2.2. Incidence of Dravet Syndrome by Mutation Type
  • 10.3. Seizure associated cases of Dravet Syndrome
  • 10.4. Gender specific Incidence of Dravet Syndrome
  • 10.5. Age specific Incidence of Dravet Syndrome
  • 10.6. Mortality associated with Dravet Syndrome

11. Spain

  • 11.1. Incident Population of Dravet Syndrome
  • 11.2. Mutations associated with Dravet Syndrome
    • 11.2.1. Incidence of Dravet Syndrome by Mutation Class
    • 11.2.2. Incidence of Dravet Syndrome by Mutation Type.
  • 11.3. Seizure associated cases of Dravet Syndrome
  • 11.4. Gender specific Incidence of Dravet Syndrome
  • 11.5. Age specific Incidence of Dravet Syndrome
  • 11.6. Mortality associated with Dravet Syndrome

12. United Kingdom

  • 12.1. Incident Population of Dravet Syndrome
  • 12.2. Mutations associated with Dravet Syndrome
    • 12.2.1. Incidence of Dravet Syndrome by Mutation Class
    • 12.2.2. Incidence of Dravet Syndrome by Mutation Type
  • 12.3. Seizure associated cases of Dravet Syndrome
  • 12.4. Gender specific Incidence of Dravet Syndrome
  • 12.5. Age specific Incidence of Dravet Syndrome
  • 12.6. Mortality associated with Dravet Syndrome

13. Austria

  • 13.1. Incident Population of Dravet Syndrome
  • 13.2. Mutations associated with Dravet Syndrome
    • 13.2.1. Incidence of Dravet Syndrome by Mutation Class
    • 13.2.2. Incidence of Dravet Syndrome by Mutation Type
  • 13.3. Seizure associated cases of Dravet Syndrome
  • 13.4. Gender specific Incidence of Dravet Syndrome
  • 13.5. Age specific Incidence of Dravet Syndrome
  • 13.6. Mortality associated with Dravet Syndrome

14. Japan

  • 14.1. Assumptions and Rationale
  • 14.2. Incident Population of Dravet Syndrome
  • 14.3. Mutations associated with Dravet Syndrome
    • 14.3.1. Incidence of Dravet Syndrome by Mutation Class
    • 14.3.2. Incidence of Dravet Syndrome by Mutation Type
  • 14.4. Seizure associated cases of Dravet Syndrome
  • 14.5. Gender specific Incidence of Dravet Syndrome
  • 14.6. Age specific Incidence of Dravet Syndrome
  • 14.7. Mortality associated with Dravet Syndrome

15. Australia

  • 15.1. Assumptions and Rationale
  • 15.2. Incident Population of Dravet Syndrome
  • 15.3. Mutations associated with Dravet Syndrome
    • 15.3.1. Incidence of Dravet Syndrome by Mutation Class
    • 15.3.2. Incidence of Dravet Syndrome by Mutation Type
  • 15.4. Seizure associated cases of Dravet Syndrome
  • 15.5. Gender specific Incidence of Dravet Syndrome
  • 15.6. Age specific Incidence of Dravet Syndrome
  • 15.7. Mortality associated with Dravet Syndrome

16. Treatment of Dravet Syndrome

  • 16.1. Current Treatment Practices
    • 16.1.1. First-Line Therapies: Valproic Acid and Clobazam
    • 16.1.2. Second-Line Therapies
    • 16.1.3. Third Line of Therapies
  • 16.2. Treatment Algorithm

17. Unmet Needs

18. Marketed Drugs

  • 18.1. Diacomit: Biocodex
    • 18.1.1. Drug Description
    • 18.1.2. Mechanism of Action
    • 18.1.3. Regulatory Milestones
    • 18.1.4. Advantages & Disadvantages
    • 18.1.5. Safety and Efficacy
    • 18.1.6. Product Profile
  • 18.2. Epidiolex: GW Pharmaceuticals
    • 18.2.1. Drug Description
    • 18.2.2. Mechanism of Action
    • 18.2.3. Regulatory Milestones
    • 18.2.4. Advantages & Disadvantages
    • 18.2.5. Safety and Efficacy
    • 18.2.6. Product Profile

19. Emerging Therapies

  • 19.1. FINTEPLA: Zogenix
    • 19.1.1. Product Description
    • 19.1.2. Other Developmental Activities
    • 19.1.3. Regulatory Milestones
    • 19.1.4. Clinical Development
    • 19.1.5. Safety and Efficacy
    • 19.1.6. Product Profile

20. Dravet Syndrome: 9 Major Market Analysis

  • 20.1. Key Findings
  • 20.2. Total Market Size of Dravet Syndrome in 9MM
  • 20.3. 9 MM Size of Dravet Syndrome by Line of Treatment

21. Market Outlook by Country

  • 21.1. The United States: Market Outlook
  • 21.2. United States Market Size
    • 21.2.1. Total Market Size of Dravet Syndrome
    • 21.2.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
  • 21.3. EU-6 Countries: Market Outlook
  • 21.4. Germany Market Size
    • 21.4.1. Total Market Size of Dravet Syndrome
    • 21.4.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
  • 21.5. France Market Size
    • 21.5.1. Total Market Size of Dravet Syndrome
    • 21.5.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
  • 21.6. Italy Market Size
    • 21.6.1. Total Market Size of Dravet Syndrome
    • 21.6.2. Dravet Syndrome Market Size by by Line of Treatment (LoT)
  • 21.7. Spain Market Size
    • 21.7.1. Total Market Size of Dravet Syndrome
    • 21.7.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
  • 21.8. The United Kingdom Market Size
    • 21.8.1. Total Market Size of Dravet Syndrome
    • 21.8.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
  • 21.9. Austria Market Size
    • 21.9.1. Total Market Size of Dravet Syndrome
    • 21.9.2. Dravet Syndrome Market Size by Line of Treatment (LoT)
  • 21.10. Japan: Market Outlook
  • 21.11. Japan: Market Size
    • 21.11.1. Total Market Size of Dravet Syndrome
    • 21.11.2. Dravet Syndrome Market Size by Line of Treatment (LoT)

22. Market Drivers

23. Market Barriers

24. Appendix

25. Report Methodology

  • 25.1. Sources Used

26. DelveInsight Capabilities

27. Disclaimer

28. About DelveInsight

Back to Top